So far, gene therapy and cell therapy have been long on promise and short on results. Neurotech S.A. hopes to refine what has been a hit-or-miss approach, using engineered immortalized cerebral endothelial cells or retinal epithelial cells with targeting capacity to deliver therapeutic proteins in central nervous system (CNS) and ophthalmic indications.

"We're in between gene and cell therapy but different from both," said CEO Tom Shepherd. "Although we're using transfected cells, unlike in vivo gene therapy we're not transducing host cells with a gene. Instead, we're using genetically modified cells as a means of delivering proteins, like a protein factory."